A life-long positive benefit/risk ratio in healthy subjects

As we learned in week 1, a product’s B/R is determined in its therapeutic context. However, some medicinal products are designed to be taken by healthy individuals. Thus, regulatory authorities are understandably averse to risks in this target population, allowing only relatively mild side effects that do not last long and are fully reversible.